Cell therapy with autologous donor-specific regulatory T cells (Tregs) is a promising strategy
to minimize immunosuppression in transplant recipients. Chimeric antigen receptor (CAR)
technology has recently been used successfully to generate donor-specific Tregs and
overcome the limitations of enrichment protocols based on repetitive stimulations with
alloantigens. However, the ability of CAR-Treg therapy to control alloreactivity in
immunocompetent recipients is unknown. We first analyzed the effect of donor-specific CAR …